Interaction of CD44 and its ligand, hyaluronan, activates the Src/ERK signaling pathway, leading to acquired resistance to PI3Kα inhibitor, BLY719, in luminal breast carcinomas [39]. Here, CD44 is linked to breast carcinoma.